ASCLETIS-B (01672.HK): ASC36_35FDC preclinical data presented at EASD 2026
- ASC36_35FDC is a combination therapy independently developed using Ascletis' proprietary structure-based AI-assisted drug discovery (AISBDD) and ultra-long-acting drug development platform (ULAP) technologies, combining an amylin receptor agonist with a GLP-1R/GIPR dual agonist to leverage the complementary effects of the two mechanisms.
- In DIO rat and non-human primate (NHP) models, ASC36_35FDC showed more significant additional weight loss and food intake suppression compared with ASC35 monotherapy, suggesting a potential synergistic effect.
NewTimeSpace News: On 2 October 2026, Ascletis Pharma Inc. (stock code: 01672) announced that key preclinical data for ASC36_35FDC (a fixed-dose combination of ASC36 and ASC35) were presented at the 62nd Annual Meeting of the European Association for the Study of Diabetes (EASD), held in Milan, Italy from 28 September to 2 October 2026. ASC36_35FDC is a monthly to quarterly fixed-dose combination injectable of ASC36, a peptide amylin receptor agonist, and ASC35, a peptide GLP-1R/GIPR agonist. The Company also stated that it has developed a once-weekly oral tablet of ASC36_35FDC.
The data showed that in diet-induced obesity (DIO) rats, ASC36_35FDC administered at 5 nmol/kg_8 nmol/kg once every 2 days for a total of 7 doses produced a 24.8% body weight reduction on Day 14, compared with 12.5% for the eloralintide/tirzepatide combination group and 16.8% for the MET-233i/tirzepatide combination group, representing relative improvements in weight loss of 98% and 47% respectively. In non-human primates, the observed half-lives of ASC36 and ASC35 in ASC36_35FDC were up to 781 hours (approximately 33 days) and 721 hours (approximately 30 days) respectively, supporting monthly and potentially quarterly subcutaneous dosing in humans. In terms of formulation stability, under simulated storage conditions (200 rpm, 25°C, 168 hours), no fibrillation-induced aggregation was observed for ASC36_35FDC across different concentrations, vehicles and pH conditions. The Company cautioned that it cannot guarantee that it will ultimately be able to successfully develop, market and/or commercialise ASC36_35FDC.
NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.
- ASCLETIS-B (01672.HK): Initiates US Phase I Study of Oral Amylin Receptor Agonist Peptide ASC36 for Obesity; Up to 13.2% Weight Loss in Non-human Primates
- ASCLETIS-B (01672.HK): Included in Stock Connect list under Shanghai-Hong Kong and Shenzhen-Hong Kong schemes effective 7 September
- ASCLETIS-B(01672.HK)2026 Interim Report - Profit Attributable to Shareholders stood at loss of CNY 319.67 million, loss widened by 263.46% YoY
- ASCLETIS-B (01672.HK): First subject dosed in global Phase III program of oral GLP-1 agonist ASC30 for long-term weight management, targeting ~4,600 subjects
- Ascletis-B (01672.HK): Oral Small-molecule GLP-1 ASC30 Initiates Global Phase III Clinical Trials; First-in-class Triple-target FDC Achieves 15.2% Weight Loss in Preclinical Studies
